Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-06-28
2009-08-25
Carlson, Karen Cochrane (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
07579314
ABSTRACT:
The invention concerns a cell support comprising an RGD-enriched gelatine that has a more even distribution of RGD sequences than occurring in a natural gelatine and with a minimum level of RGD sequences. More precise the percentage of RGD sequences related to the total number of amino acids is at least 0.4 and if the RGD-enriched gelatine comprises 350 amino acids or more, each stretch of 350 amino acids contains at least one RGD motif. Preferably the RGD-enriched gelatines are prepared by recombinant technology, and have a sequence that is derived from a human gelatine or collagen amino acid sequence. The invention also relates to RGD-enriched gelatines that are used for attachment to integrins. In particular The RGD-enriched gelatines of the invention are suitable for coating a cell culture support for growing anchor-dependant cell types. Further, the RGD-enriched gelatines of the invention may find use in medical applications, in particular as a coating on implant or transplant material or as a component of drug delivery systems.
REFERENCES:
patent: 6140072 (2000-10-01), Ferrari et al.
patent: 6146824 (2000-11-01), Bar-Shavit
patent: 6992172 (2006-01-01), Chang et al.
patent: WO 98/18918 (1998-05-01), None
patent: WO 02/064625 (2002-08-01), None
Zhao et al. 2002; Synthesis of RGD containing peptides and their bioactivities. Preparative Biochemistry & Biotechnology 32(4): 363-3890.
Oku et al. 1996; Liposomal Arg-Gly-Asp analogs effectively inhibit metastatic B16 melanoma colonization in murine lungs. Life Sciences 58(24): 2263-2270.
U.S. Appl. No. 11/770,019, filed Jun. 28, 2007, Bouwstra et al.
U.S. Appl. No. 11/770,197, filed Jun. 28, 2007, Bouwstra et al.
U.S. Appl. No. 11/770,256, filed Jun. 28, 2007, Bouwstra et al.
U.S. Appl. No. 11/770,271, filed Jun. 28, 2007, Bouwstra et al.
International Search Report of PCT/NL2004/00208; Feb. 16, 2005.
Wierzba et al., “Production and Properties fo a Bifunctional Fusion..”, Biotechnology and Bioengineering . . . , Jul. 20, 1995, vol. 47, pp. 147-154, John Wiley & Sons, New York,US.
Bouwstra Jan Bastiaan
Toda Yuzo
Van Es Andries Johannes Jozef
Carlson Karen Cochrane
Fuji Film Manufacturing Europe B.V.
K & L Gates LLP
LandOfFree
Use of RGD-enriched gelatine-like proteins for inhibition of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of RGD-enriched gelatine-like proteins for inhibition of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of RGD-enriched gelatine-like proteins for inhibition of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4107014